Articles related to GYNECOLOGICAL CANCERS

Vaginal fluid collection via tampon under clinical supervision followed by bisulfite conversion and long-probe quantitative amplified signal assays for methylated DNA marker analysis.

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.

A comprehensive analysis of 176,601 cancer cases demonstrates that long-acting reversible contraceptives offer a cancer risk profile comparable to oral contraceptives, with data showing a 20-30% reduction in gynecologic cancer risk and a modest increase in breast cancer risk that returns to baseline after cessation.

Comprehensive genetic profiling now plays a central role in ovarian cancer management, with mandatory offering of both germline and somatic testing for all patients at diagnosis.

Virginia Commonwealth University’s latest research introduces a novel, urine-based test for ovarian cancer, utilizing nanotechnology to identify specific peptides, offering a new avenue for early detection and enhancing patient care strategies.

The recent study on bevacizumab’s effect on ovarian cancer progression provides valuable insights into its initial benefits and subsequent risks.